A Study to Assess the Drug-drug Interaction of BMS-963272 and Rosuvastatin

Bristol-Myers Squibb (BMS)

Status and phase: Completed; Phase 1

Conditions: Healthy Participants

Treatments: Drug: rosuvastatin; Drug: BMS-963272

Study type: Interventional

Funder types: Industry

Identifiers

NCT04124003

MB006-018

Details and patient eligibility

About

Phase 1 study that assesses the effect of BMS-963272 on exposure of rosuvastatin in healthy participants

Enrollment: 28 patients

Sex: All

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• Healthy participants, as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations
• Women must not be of childbearing potential (WNOCBP)
• Women and men must agree to follow instructions for methods of contraception

Exclusion Criteria:

• Any significant acute or chronic medical condition that presents a potential risk to the participant and/or may compromise the objectives of the study.
• Any major surgery within 4 weeks of study drug administration
• Any blood transfusion or donation of blood to a blood bank or in a clinical study within 4 weeks of study drug administration
• Previous treatment with BMS-963272
• Participants who smoke, as well as, those who have stopped smoking less than 6 months prior to day 1

Other protocol-defined inclusion/exclusion criteria could apply

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

28 participants in 1 patient group

rosuvastatin + BMS-963272

Experimental group

Treatment:

Drug: BMS-963272

Drug: rosuvastatin